Smart Cells and Future Health joint statement on grossly misleading competitor allegations. Read More

Smart Cells and Future Health Joint Statement on Grossly Misleading Competitor Allegations

 In Other news, Stem Cell News

Smart Cells International (SCI) and Future Health Biobank (FHB) wish to highlight their concerns in relation to Cells4Life (C4L) circulating what they believe to be a misleading and unsupportable statement that post-cryopreservation yields of stem cells from umbilical cord blood units that are processed using industry leading cell processing technologies are substandard.

C4L states that their in-house Toticyte processing method provides 3 times more stem cells from the umbilical cord than any other cord blood processing method that they have tested, including all systems currently used in the UK.

As the majority of public and private cord blood banks use Sepax™, AXP™ or Macopress™ processing technologies, we consider that the statement propagated by C4L implies that respected establishments, including the NHSBT, Anthony Nolan Trust and transplant centres worldwide, are working with inferior and inconsistent low viable stem cell recovery levels.

Throughout the world, many thousands of patients have been successfully transplanted using cord blood units processed using Sepax™, AXP™ or Macopress™. In clinical and scientific literature, viable CD34+ post-thaw recovery levels of >70% are cited as acceptable and achievable for clinical use.

SCI and FHB undertake regular auditing of cord blood post-thaw viable stem cell recovery following processing using established and accepted technologies. This data for each organisation must undergo Human Tissue Authority (HTA) scrutiny as part of the inspection process relating to the Human Application Licence. Losses of 60-70% following cryopreservation would be unacceptable.

Both SCI and FHB are able to demonstrate an average CD34+ stem cell recovery rate above 70%. The comparative figures presented by C4L have been generated as a result of “in house” investigations and present a significantly skewed perspective on post-thaw viable CD34+ recovery following processing using our technologies.

It is the view of both SCI and FHB that they achieve notably higher post-thaw CD34+ stem cells counts than C4L do using their Toticyte method (based on data published by C4L).

SCI and FHB would like to point out that no sample processed using C4L’s Toticyte method has ever been used in a clinical application. In contrast, SCI and FHB have released many samples for successful clinical use using their proven sample processing technologies. The point being that currently, C4L has no track record in relation to clinical use.

 

Shamshad Ahmed CEO, Smart Cells International and Chris Bond Managing Director, Future Health Biobank


 

About Smart Cells International (SCI) and Future Health Biobank (FHB)

SCI and FHB are pioneers and experts in the private stem cell industry being the first two cord blood banks to be established in the UK nearly 20 years ago.

Between them, they have processed and stored more than 150,000 cord blood units from over 75 countries worldwide within their state-of-the-art UK laboratories. Today, they process and store between them, more than two thirds of all private cord blood units within the UK.

Both companies use industry leading, proven processing technologies and have released many cord blood units for successful clinical applications.

Recent Posts

Start typing and press Enter to search